2014 Committee

Dr. Susan Dent

CCON Co-Chair, Medical Oncologist, The Ottawa Hospital Cancer Centre, Ottawa, ON


Dr. Dent is a Medical Oncologist at The Ottawa Hospital Cancer Centre and Associate Professor in the Department of Medicine at the University of Ottawa.  She obtained her MD at McMaster University and completed her postgraduate training in Internal Medicine at the University of Ottawa. She continued her training in Medical Oncology in Ottawa, followed by a fellowship year in Clinical Research with the National Cancer Institute of Canada Clinical Trials Group. Conference Topic: Opening and Closing Comments


Presently, Dr. Dent is Vice Chair of the Patient Quality & Safety Committee, a member of Cancer Care Ontario Breast Disease Site Group Practice Guidelines Committee, IND working group for the Breast Cancer Disease Site Committee of the National Cancer Institute for Canada Clinical Trials Group and Grant Review Panel for the Canadian Breast Cancer Foundation and the Canadian Institute of Health Research. She is the founder of the Canadian Cardiac Oncology Network, an organization dedicated to improving our understanding of how cancer treatments impact cardiovascular health with the ultimate goal of preventing cardiotoxicity. Her areas of interest include breast cancer, treatment toxicities and cardiotoxicity.

[Contact Susan Dent]

Dr. Christine Brezden-Masley

CCON Co-Chair, Medical Oncologist, St. Michael’s Hospital, Toronto, ON


Dr. Christine Brezden-Masley is the Adjunct Scientist in the Keenan Research Centre of the Li Ka Shing Knowledge Institute of St. Michael’s Hospital and a Medical Oncologist at the St. Michael’s Hospital in Toronto. She is also an Assistant Professor and Clinical Investigator of the Department of Medicine at the University of Toronto, and Clinical Leader of the Oncology Clinical Research Group at the St. Michael’s Hospital. Dr. Brezden-Masley completed her MSc and PhD in Medical Biophysics and obtained her MD at the University of Toronto.

Conference Topic: Opening and Closing Comments


Dr. Brezden-Masley’s research interests include the study of both novel cytotoxic chemotherapeutics and molecular-targeted biologics that improve efficacy of cancer therapy through Phase 2 and 3 clinical trials for breast cancer patients and gastrointestinal cancers (colorectal and gastric cancers). Her current areas of particular interest include breast cancer pathophysiology (breast cancer diagnostics and tumour markers), quality improvement (identifying barriers to wait-times for delivery of systemic therapy), patient safety (optimizing chemotherapy drug delivery) and diagnostic imaging (improving detection of potential chemotherapy- and biologics-induced myocardial damage).

Dr. Julie Lemieux

Medical Oncologist, Hopital Saint-Sacrement, Quebec, QC


Dr. Julie Lemieux is a Medical Oncologist at “Le centre des maladies du sein Deschênes-Fabia – CHU de Québec” and Assistant Professor in the Department of Medicine at the Laval University.  She obtained her MD at Laval University and completed a Fellowship in breast cancer at Mount Sinai Hospital and obtained a Master in Clinical Epidemiology at the University of Toronto.


The Dr Lemieux’s research program focuses on the efficacy and toxicities of breast cancer treatment especially on chemotherapy-induced alopecia, cardiac toxicity associated with anti-HER2 therapy and on building an infrastructure allowing the timely and efficient evaluation of the efficacy of breast cancer treatments at a population-based level. She is also a member of the National Cancer Institute of Canada Clinical Trials Group-Quality of life committee.

Dr. Narinder Paul

Section Chief of Cardiothoracic Imaging, Site Chief for Medical Imaging, Toronto General Hospital, Toronto, ON, University Health Network and the Peter Munk Cardiac Centre


Dr. Narinder Paul is the Section Chief of Cardiothoracic Imaging and the Site Chief for Medical Imaging at Toronto General Hospital, University Health Network.  He is an Associate Professor and Section Chief for Cardiothoracic Imaging at the University of Toronto.


He received his MD degree from Southampton University Medical School (UK) and his Board certification in Internal Medicine from the Royal College of Physicians (UK). He completed his Radiology residency in the Newcastle and Leeds University Hospitals (UK) and is a Fellow of the Royal College of Radiologists (UK). Subsequently, he completed Body Imaging and Cardiothoracic Imaging Fellowships at the University of Toronto and Board certification in Radiology (Canada).

Dr. Jeffrey Sulpher

Cardiac Oncology Research Fellow, The Ottawa Hospital Cancer Centre, Ottawa, ON


Dr. Jeffrey Sulpher received his BSc.(Hons.) in Biopharmaceutical Sciences from the University of Ottawa in 2003, and his M.D. from Queen's University in 2008.  He went on to complete his internal medicine and medical oncology residencies at the University of Ottawa.  He is currently a cardiac oncology fellow at the Ottawa Hospital Cancer Centre.

Conference Topic: Cardiac Oncology Survey Results


His current research projects include the investigation of biomarkers for identification of patients at risk of treatment-induced cardiotoxicity, as well as a national physician's survey exploring issues surrounding cardiac oncology in Canada.

Dr. S. Wamique Yusuf

Associate Professor of Medicine, University of Texas, MD Anderson Cancer Center


Dr S.Wamique Yusuf is an Associate Professor of Medicine at the University of Texas MD Anderson Cancer Center. He obtained his medical degree from Dow Medical College, Karachi. He pursued his Internal Medicine training in the United Kingdom, where his research included prospective studies on the association of helicobacter pylori with fibrinogen level and coronary artery disease in elderly population and effect of spironolacatone on quality of life in patients with heart failure.


He moved to USA in 1996 and completed his cardiology fellowship from the University of Texas, Houston. He is a member of the Royal College of Physicians of Ireland and a Fellow of American College of Cardiology. He is heavily involved in the clinical training of fellows and medical students and is also the Program Co-Director for the annual ACC Cardiovascular Board Review. His clinical and research interest includes management of cardiovascular disease in patients with cancer and radiation induced cardiotoxicity.

Dr. Edith Pituskin

Assistant Clinical Professor, Radiation Oncology, Cross Cancer Institute, Edmonton, AB


Dr. Edith Pituskin is an Assistant Clinical Professor in the Department of Oncology, University of Alberta. She is co-lead of the Edmonton Cardio-Oncology REsearch (ENCORE) program. Her PhD studies were specifically focused on cardiotoxicity of various cancer therapies. Dr Pituskin’s research interests include various preventive and treatment strategies of cardiotoxic cancer therapies, advanced practice and multidisciplinary team working, improving adherence to oral cancer therapies and program development.

Conference Topic: Opportunities and challenges in cardio-oncology clinical research

Dr. Paaladinesh Thavendiranathan

Cardiologist, Toronto General Hospital, Toronto, ON


Dr. Thavendiranathan in a Cardiologist and an Assistant Professor of Medicine at the Peter Munk Cardiac Center at the Toronto General Hospital (University of Toronto). He completed his Internal Medicine and Cardiology training at University of Toronto, followed by training in advanced cardiac imaging (echocardiography, cardiac CT, and cardiac MRI) at the Ohio State University Medical Center and the Cleveland Clinic.

Conference Topic: Role of cardiac MRI in the assessment of cardiotoxicity


His primary clinical interest is in the care of patients with cardiac toxicity from cancer therapy and currently runs the Cardiac Conditions in Oncology Program at University Health Network. As a Clinician Investigator his primary research interests are in use of novel imaging methods to identify early cardiac injury in patients receiving potentially cardio-toxic therapy and in studying various cardio-protective medications to prevent cardio-toxicity.

Dr. Sou Kishore Thain

Radiation Oncologist, Cancer Centre of Southeastern Ontario, Kingston, ON


Dr. Thain is a Radiation Oncologist at the Cancer Center of Southeastern Ontario and an Assistant Professor at Queen's University in Kingston, Ontario. He completed his specialist training in the UK. His areas of interest include breast cancer, lung cancer, CNS tumors and prevention of cardiotoxicity. He is the Chair of the CNS Tumor Multidisciplinary Group and Co-Chair of the Breast Cancer Multidisciplinary Group in the region.


He has co-authored several guidelines, including "Clinical Practice Guidelines for the Care and Treatment of Breast Cancer", CMAJ, 1998; "Questions and Answers on Breast Cancer for Women and their Physicians", CMAJ, 1998; and "Questions and Answers on Breast Cancer for Women and their Physicians", 2nd Ed, 2001.

Dr. Christine Simmons

Medical Oncologist, BC Cancer Agency, Vancouver General Hospital, Vancouver, BC